Literature DB >> 18039197

Treatment of the spasticity in children with cerebral palsy.

Ajsa Meholjić-Fetahović1.   

Abstract

Botulinum toxin is a natural purified protein and one of the strongest biological poisons--neurotoxin. It is produced by the bacterium Clostridium botulinum. Its medical usage started in USA in 1981 and in Europe in 1992. There are seven different immune types of the toxin: A, B, C1, D, E, F and G. Toxin types A and B are used to decrease muscular spasticity. Botulinum toxin prevents the formation of acetylcholine from cholinergic nerve tissues in muscles, which in the end irreversibly destroys neuromuscular synapses. It is called temporary local chemodenervation. It does not affect the synthesis of acetylcholine. As it affects neuromuscular bond it also affects one of the symptoms of cerebral palsy--spasticity. Decreasing the spasticity of children with cerebral palsy leads to the improvement of conscious movements, muscles are less toned, passive mobility is improved, orthosis tolerance is also improved, and the child is enabled to perform easier and better motor functions such as crawling, standing and walking. Since the action of Botulinum toxin is limited to 2-6 months, new neural collaterals are formed and neuromuscular conductivity is reestablished which in the end once again develops a muscular spasm. This leads to a conclusion that botulinum toxin should again be applied into spastic muscles. It is very important for good effect of Botulinum toxin to set the goals of the therapy in advance. The goals include improvement of a function, prevention of contractions and deformities, ease of care and decrease of pain for children with cerebral palsy. After application of botulinum toxin, it is necessary to perform adequate and intensive physical treatment with regular monitoring of effects. This work shows a case of a boy with spastic form of cerebral palsy. After being rehabilitated using Vojta therapy and Bobath concept and the conduct of certain physical procedures, botulinum toxin is administered into his lower limbs' muscles and kinesiotherapy is intensified. After the administration of botulinum toxin significant functional improvement is noted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18039197      PMCID: PMC5728612          DOI: 10.17305/bjbms.2007.3028

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  10 in total

Review 1.  Safety of botulinum toxin type A: a systematic review and meta-analysis.

Authors:  Markus Naumann; Joseph Jankovic
Journal:  Curr Med Res Opin       Date:  2004-07       Impact factor: 2.580

2.  The effect of botulinum toxin type A injection into the gastrocnemius muscle on sit-to-stand transfer in children with spastic diplegic cerebral palsy.

Authors:  Eun Sook Park; Chang Il Park; Hyun Chung Chang; Chan Woo Park; Don Shin Lee
Journal:  Clin Rehabil       Date:  2006-08       Impact factor: 3.477

Review 3.  Botulinum toxin. From poison to medicine.

Authors:  L E Davis
Journal:  West J Med       Date:  1993-01

4.  Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial.

Authors:  L A Koman; A Brashear; S Rosenfeld; H Chambers; B Russman; M Rang; L Root; E Ferrari; J Garcia de Yebenes Prous; B P Smith; C Turkel; J M Walcott; P T Molloy
Journal:  Pediatrics       Date:  2001-11       Impact factor: 7.124

5.  Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity.

Authors:  Edward M Goldstein
Journal:  J Child Neurol       Date:  2006-03       Impact factor: 1.987

Review 6.  Botulinum toxin in children with cerebral palsy.

Authors:  Pratibha Singhi; Munni Ray
Journal:  Indian J Pediatr       Date:  2004-12       Impact factor: 1.967

Review 7.  Botulinum toxin type A in the management of equinus in children with cerebral palsy: an evidence-based economic evaluation.

Authors:  J Houltram; I Noble; R N Boyd; I Corry; P Flett; H K Graham
Journal:  Eur J Neurol       Date:  2001-11       Impact factor: 6.089

8.  Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy.

Authors:  T Ubhi; B B Bhakta; H L Ives; V Allgar; S H Roussounis
Journal:  Arch Dis Child       Date:  2000-12       Impact factor: 3.791

Review 9.  Cerebral palsy.

Authors:  L Andrew Koman; Beth Paterson Smith; Jeffrey S Shilt
Journal:  Lancet       Date:  2004-05-15       Impact factor: 79.321

10.  Botulinum toxin type B improves the speed of reaching in children with cerebral palsy and arm dystonia: an open-label, dose-escalation pilot study.

Authors:  Terence D Sanger; Sahana N Kukke; Sara Sherman-Levine
Journal:  J Child Neurol       Date:  2007-01       Impact factor: 1.987

  10 in total
  1 in total

Review 1.  Intrathecal baclofen, selective dorsal rhizotomy, and extracorporeal shockwave therapy for the treatment of spasticity in cerebral palsy: a systematic review.

Authors:  Amogh Kudva; Mickey E Abraham; Justin Gold; Neal A Patel; Julian L Gendreau; Yehuda Herschman; Antonios Mammis
Journal:  Neurosurg Rev       Date:  2021-04-19       Impact factor: 3.042

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.